Hi_老虎社区_美港股上老虎

EAvenue
2021-12-22

Eisai-Biogen Alzheimer's drug difficult to assess-Japan ministry

TOKYO (Reuters) -- A Japanese health ministry panel said on Wednesday that inconsistent trial result

Eisai-Biogen Alzheimer's drug difficult to assess-Japan ministry

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":691853321,"tweetId":"691853321","gmtCreate":1640171188991,"gmtModify":1640171323155,"author":{"id":3584939916187250,"idStr":"3584939916187250","authorId":3584939916187250,"authorIdStr":"3584939916187250","name":"EAvenue","avatar":"https://static.tigerbbs.com/e3beb412a0aa565cfaac4f68f1721fd6","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Hi</p></body></html>","htmlText":"<html><head></head><body><p>Hi</p></body></html>","text":"Hi","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/691853321","repostId":1147037546,"repostType":4,"repost":{"id":"1147037546","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640170941,"share":"https://www.laohu8.com/m/news/1147037546?lang=&edition=full","pubTime":"2021-12-22 19:02","market":"us","language":"en","title":"Eisai-Biogen Alzheimer's drug difficult to assess-Japan ministry","url":"https://stock-news.laohu8.com/highlight/detail?id=1147037546","media":"Reuters","summary":"TOKYO (Reuters) -- A Japanese health ministry panel said on Wednesday that inconsistent trial result","content":"<p>TOKYO (Reuters) -- A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.</p>\n<p>Tokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.</p>\n<p>In a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.</p>\n<p>Eisai and Biogen have jointly developed three experimental drugs for the brain-wasting disease, which affects millions around the world and has not seen a new treatment in decades.</p>\n<p>Expectations among patient groups and investors for the drug have been on a roller coaster for years. It was nearly abandoned after disappointing trial results in 2019, but Biogen revived it after reviewing data showing that higher doses of the drug could slow disease progression.</p>\n<p>The U.S. Food and Drug Administration (FDA) approved the drug earlier this year despite objections from an outside advisory panel its clinical benefit was unproven.</p>\n<p>Biogen said on Monday it would cut the U.S. price of Aduhelm, known scientifically as aducanumab, in half amid complaints about its high cost and slower than expected sales.</p>\n<p>More than 8 million people in Japan are believed to have dementia or cognitive impairment, while treatment of Alzheimer's patients costs an estimated 7.4 trillion yen ($65 billion) per year.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eisai-Biogen Alzheimer's drug difficult to assess-Japan ministry</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEisai-Biogen Alzheimer's drug difficult to assess-Japan ministry\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-22 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TOKYO (Reuters) -- A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.</p>\n<p>Tokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.</p>\n<p>In a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.</p>\n<p>Eisai and Biogen have jointly developed three experimental drugs for the brain-wasting disease, which affects millions around the world and has not seen a new treatment in decades.</p>\n<p>Expectations among patient groups and investors for the drug have been on a roller coaster for years. It was nearly abandoned after disappointing trial results in 2019, but Biogen revived it after reviewing data showing that higher doses of the drug could slow disease progression.</p>\n<p>The U.S. Food and Drug Administration (FDA) approved the drug earlier this year despite objections from an outside advisory panel its clinical benefit was unproven.</p>\n<p>Biogen said on Monday it would cut the U.S. price of Aduhelm, known scientifically as aducanumab, in half amid complaints about its high cost and slower than expected sales.</p>\n<p>More than 8 million people in Japan are believed to have dementia or cognitive impairment, while treatment of Alzheimer's patients costs an estimated 7.4 trillion yen ($65 billion) per year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147037546","content_text":"TOKYO (Reuters) -- A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.\nTokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.\nIn a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.\nEisai and Biogen have jointly developed three experimental drugs for the brain-wasting disease, which affects millions around the world and has not seen a new treatment in decades.\nExpectations among patient groups and investors for the drug have been on a roller coaster for years. It was nearly abandoned after disappointing trial results in 2019, but Biogen revived it after reviewing data showing that higher doses of the drug could slow disease progression.\nThe U.S. Food and Drug Administration (FDA) approved the drug earlier this year despite objections from an outside advisory panel its clinical benefit was unproven.\nBiogen said on Monday it would cut the U.S. price of Aduhelm, known scientifically as aducanumab, in half amid complaints about its high cost and slower than expected sales.\nMore than 8 million people in Japan are believed to have dementia or cognitive impairment, while treatment of Alzheimer's patients costs an estimated 7.4 trillion yen ($65 billion) per year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1124,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Eisai-Biogen Alzheimer's drug difficult to assess-Japan ministry

评论（1）

热议股票